Iris Kuss

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +8

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela et al. · New England Journal of Medicine · 2019 · 922 citations · Full text

Medicine, Oncology, Pharmacology +15

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela et al. · New England Journal of Medicine · 2020 · 360 citations · Full text

Medicine, Oncology, Pharmacology +16

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Maha Hussain, Bertrand Tombal, Fred Saad et al. · Journal of Clinical Oncology · 2023 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore et al. · Journal of Clinical Oncology · 2024 · 141 citations · Full text

Medicine, Oncology, Pharmacotherapy +17